Major Trial Finds AF Ablation No Better Than Placebo for Quality of Life

Key points

• The PVI-SHAM-AF trial randomized 262 patients with symptomatic AF to either catheter ablation or a sham procedure, with a 2:1 ratio favoring ablation.
• The primary endpoint, the AF Effect on Quality of Life (AFEQT) score, improved from 61.3 to 81.1 in the ablation group and from 59.2 to 74.9 in the sham group, with a non-significant difference of 2.6 points between groups.
• Ablation significantly reduced AF recurrence (27% vs 48%) and burden (11.6% vs 23.6%) compared to the sham group, but these objective improvements did not translate to superior quality of life outcomes.
• The trial involved 1,200 screened patients from nine centers in Germany and Poland, with a median age in the late 60s and 51% female participants.
• The results suggest that the perceived benefits of AF ablation may be largely due to placebo effects, including the caring signal of an invasive procedure and subsequent medical attention, rather than the elimination of arrhythmia itself.

Background

Prior to this trial, two smaller sham-controlled studies (SHAM PVI in the UK and PFA-SHAM in the Czech Republic) had suggested that AF ablation provided quality of life benefits resistant to placebo effects. Electrophysiologists had performed AF ablation for over 25 years without placebo-controlled evidence, relying on the assumption that reduced AF burden drove patient-reported improvements. The PVI-SHAM-AF trial is the first large-scale, multicenter randomized controlled trial to directly test this assumption in a broad patient population.

Why it matters

The findings challenge the foundational rationale for AF ablation, suggesting that the procedure may not provide the quality of life benefits previously attributed to it. This could lead to a reevaluation of ablation indications, potentially slowing the rapid increase in procedures and prompting greater focus on understanding the underlying pathophysiology of AF rather than solely pursuing pulmonary vein isolation. The results highlight the significant role of placebo effects in subjective symptom reporting and the need for more rigorous evidence in electrophysiology.

What to watch

The trial results are expected to stimulate further research into the pathophysiology of AF and the mechanisms behind patient-reported symptom improvement. Clinicians may reconsider the routine use of ablation for mild to moderately symptomatic patients, and the medical community may face increased scrutiny regarding the necessity of invasive procedures without clear quality of life benefits. Future trials may need to explore longer follow-up periods and different patient populations to clarify the role of ablation in AF management.